Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Tvardi Therapeutics (NASDAQ: TVRD) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 12:00 PM PT. Management will discuss new Phase 2 REVERT IPF clinical trial data for TTI-101 released the same day, which the company described as showing encouraging signals across fibrosis markers, inflammatory markers, and pulmonary function tied to STAT3 inhibition. The presentation will be held in California East at The Westin St. Francis and will be webcast on the Tvardi investor website; a replay will be available for ~90 days.

News Market Reaction

+8.74%

14 alerts

+8.74% News Effect

+12.5% Peak in 24 hr 24 min

+$4M Valuation Impact

$44M Market Cap

1.3x Rel. Volume

On the day this news was published, TVRD gained 8.74%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.5% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $44M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference number: 44th Conference dates: January 12–15, 2026 Presentation time: 12:00 PM PT +1 more

4 metrics

Conference number 44th 44th Annual J.P. Morgan Healthcare Conference

Conference dates January 12–15, 2026 J.P. Morgan Healthcare Conference schedule

Presentation time 12:00 PM PT Company podium presentation slot on January 15, 2026

Webcast replay period 90 days Replay availability following the conference

Market Reality Check

Price: $3.72 Vol: Volume 87,461 versus 20-d...

low vol

$3.72 Last Close

Volume Volume 87,461 versus 20-day average 134,389 (relative volume 0.65). low

Technical Shares at $3.89, trading below 200-day MA $20.29, 91.09% below 52-week high and 4.01% above 52-week low.

Peers on Argus

TVRD fell 1.02% while peers like ABEO (+0.97%), CTMX (+3.61%), DSGN (+5.45%), IM...

TVRD fell 1.02% while peers like ABEO (+0.97%), CTMX (+3.61%), DSGN (+5.45%), IMRX (+22.14%) and LBRX (+5.48%) traded higher, indicating stock-specific dynamics rather than a sector-wide move.

Historical Context

5 past events · Latest: Nov 18 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 18	Conference participation	Neutral	+2.2%	Announcement of participation in Piper Sandler healthcare conference and webcast.
Nov 13	Earnings and update	Negative	-3.1%	Q3 2025 results with REVERT IPF miss and going-concern runway commentary.
Nov 04	Conference participation	Neutral	-2.7%	Jefferies London conference presentation and investor meetings announcement.
Oct 13	Clinical trial update	Negative	-83.9%	Preliminary Phase 2 REVERT IPF results showing study did not meet goals.
Aug 21	Conference participation	Neutral	-0.9%	Cantor Global Healthcare Conference fireside chat and investor meetings.

Pattern Detected

A major negative REVERT IPF data update on Oct 13, 2025 coincided with a sharp -83.92% move, while conference and earnings communications around late 2025 showed smaller single‑digit price reactions.

Recent Company History

Over the last six months, Tvardi’s key events centered on conferences, financial updates, and the REVERT IPF program. A preliminary Phase 2 REVERT IPF update on Oct 13, 2025 reported the study did not meet goals and coincided with a -83.92% move. Subsequent Q3 2025 results on Nov 13, 2025 highlighted net loss of $5.5M and going-concern language, with a -3.07% reaction. Multiple conference participations in August, November, and December 2025 produced modest single‑digit moves. Today’s JPM conference appearance continues this pattern of investor-outreach focused news.

Market Pulse Summary

The stock moved +8.7% in the session following this news. A strong positive reaction aligns with inv...

Analysis

The stock moved +8.7% in the session following this news. A strong positive reaction aligns with investors focusing on renewed interest in Tvardi’s IPF program and visibility from the high-profile J.P. Morgan conference. Historically, conference and corporate update news produced single‑digit moves, while the major REVERT IPF setback on Oct 13, 2025 drove a much larger -83.92% decline. Any outsized upside move could be sensitive to prior concerns flagged in recent filings, including going-concern language and clinical risk around TTI‑101.

Key Terms

phase 2, clinical trial, idiopathic pulmonary fibrosis, fibrosis, +3 more

7 terms

phase 2 medical

"new Phase 2 REVERT IPF clinical trial data for TTI-101 reported today."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

clinical trial medical

"Phase 2 REVERT IPF clinical trial data for TTI-101 reported today."

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

idiopathic pulmonary fibrosis medical

"Phase 2 REVERT IPF clinical trial data for TTI-101 in Podium Presentation"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

fibrosis medical

"signals across fibrosis, inflammatory markers and pulmonary function"

Fibrosis is the process where excess scar tissue forms in an organ or tissue, often as a response to injury or long-term damage. This buildup can impair normal function, much like thickening insulation reduces the effectiveness of a wire. For investors, fibrosis is significant because it can signal ongoing health issues that may lead to increased medical costs or influence a company’s performance in healthcare-related sectors.

inflammatory markers medical

"signals across fibrosis, inflammatory markers and pulmonary function"

Inflammatory markers are measurable substances in blood or tissue—such as certain proteins—that rise or fall when the body has inflammation, like warning lights on a dashboard signaling an internal problem. Investors watch them because changes in these markers can indicate whether a drug or treatment is working, affect clinical trial outcomes, regulatory decisions, and ultimately influence the commercial prospects and valuation of healthcare companies.

pulmonary function medical

"signals across fibrosis, inflammatory markers and pulmonary function"

Pulmonary function describes how well the lungs take in air, move oxygen into the blood and clear out carbon dioxide — essentially how efficiently the respiratory system works. For investors, it matters because drugs, devices or treatments that improve or measure pulmonary function can affect patient outcomes, regulatory approval and market size; think of it like a car’s fuel efficiency rating for the body’s breathing system.

stat3 medical

"therapies targeting STAT3 to treat fibrosis-driven diseases"

STAT3 is a protein inside cells that acts like a control knob for turning sets of genes on or off, influencing cell growth, survival and immune responses. For investors, STAT3 matters because drugs or tests that block or measure its activity can be used to treat or track cancers and inflammatory diseases, so progress on STAT3-targeted therapies or diagnostics can affect the value and prospects of biotech and pharmaceutical firms.

AI-generated analysis. Not financial advice.

Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Presentation

HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will deliver a company presentation during the 44^th Annual J.P. Morgan Healthcare Conference, being held January 12^th – 15^th, 2026, in San Francisco, CA.

During the presentation, Tvardi will discuss and provide additional context around the new Phase 2 REVERT IPF clinical trial data for TTI-101 reported today. These new data demonstrate encouraging signals across fibrosis, inflammatory markers and pulmonary function, further supporting the impact of TTI-101 on the inhibition of STAT3 in fibrosis and inflammation. For additional information regarding today’s Phase 2 REVERT IPF data announcement, please visit here.

Details are as follows:

44^th Annual J.P. Morgan Healthcare Conference
Format: Company presentation
Date: Thursday, January 15, 2026
Time: 12:00 PM PT
Location: California East at The Westin St. Francis

The audio webcast and corporate presentation will be accessible on the Tvardi Investors’ website. A replay of the webcast will be available for approximately 90 days following the conference.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting clinical trials with TTI-101 in hepatocellular carcinoma (NCT05440708) and TTI-109 in healthy volunteers. To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

Contacts:

For Tvardi:
Tvardi Investor Relations
ir@tvardi.com

PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com

Cautionary Statement Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the anticipated benefits of Tvardi’s product candidates and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials; the significant net losses Tvardi has incurred since inception; Tvardi’s ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi’s clinical trials; the outcome of preclinical testing and clinical trials of the Tvardi’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Tvardi’s product candidates; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; Tvardi’s anticipated cash runway; Tvardi’s ability to attract, hire, and retain skilled executive officers and employees; Tvardi’s ability to protect its intellectual property and proprietary technologies; Tvardi’s reliance on third parties, contract manufacturers, and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and Tvardi’s other documents subsequently filed with or furnished to the SEC, all of which are available on the SEC’s website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. The company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

FAQ

When is Tvardi Therapeutics (TVRD) presenting at the J.P. Morgan Healthcare Conference?

Tvardi will present on January 15, 2026 at 12:00 PM PT in California East at The Westin St. Francis.

What will Tvardi discuss about TTI-101 during the TVRD presentation on January 15, 2026?

Management will discuss new Phase 2 REVERT IPF data for TTI-101 showing encouraging signals in fibrosis markers, inflammatory markers, and pulmonary function.

How can investors watch Tvardi's (TVRD) J.P. Morgan presentation and is there a replay?

The presentation will be audio webcast on the Tvardi investor website and a replay will be available for approximately 90 days after the conference.

Does the January 8, 2026 announcement say the Phase 2 REVERT IPF data are definitive for TTI-101?

The announcement reports encouraging signals across specified markers; it does not state the data are definitive or provide regulatory conclusions.

Will Tvardi (TVRD) provide additional context on the Phase 2 REVERT IPF results at the conference?

Yes; management will provide additional context and discussion around the new Phase 2 REVERT IPF data during the presentation.